Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combining MEK inhibitors with BH3 mimetics, which competitively bind to BCL-XL or MCL-1 and liberate BIM, can induce apoptosis and lead to regression of KRAS-mutant tumors12,16,17.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [17]
In the citing paper
“Our finding that LKB1 regulates the apoptotic dependency of KRAS-mutant lung cancers is unexpected, as genomic features associated with sensitivity to BH3 mimetics in oncogene-addicted solid tumors have been elusive12,16,17.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [17]
In the citing paper
“Inhibition of MEK/ERK signaling leads to BIM accumulation and increases apoptotic priming in oncogene-driven cancers treated with various targeted therapies, driving cells into an MCL-1 and/or BCL-XL dependent state15,17.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [17]
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“In addition, it is possible that certain tumour types that do not harbour mutations in genes encoding oncogenic kinases may still benefit from a combination therapy of targeted OKI plus a BH3 mimetic, similar to the benefit seen for erlotinib when used as a single agent across all subgroups of NSCL”
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679 · cited 1×
“BIM and PUMA can bind and sequester all anti-apoptotic Bcl-2 family members with high affinity and are thus potent killers, whereas other BH3-only proteins, such as Bcl-2 antagonist of cell death ( BAD ) and NOXA (also known as PMAIP1), bind only certain anti-apoptotic members (BAD binds BCL-2, BCL-X L (also known as…”
BackgroundSelf-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“, such as the T790M mutation in EGFR, which confers resistance to gefitinib and erlotini”
BackgroundAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 1×
“The best characterized BH3 mimetic is ABT-737, generated by Abbott Laboratories through a combination of NMR-based screening, parallel synthesis and structure-based desig”
BackgroundTargeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Cited by
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Self-citationCancer and Radiation Therapy: Current Advances and Future Directions
Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K.-W. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.3635 · Cited by 2,880
“Apoptosis: Programmed cell death or apoptosis is a major cell death mechanisms involved in cancer therapy and in radiation therapy in particular [38, 39, 40].”
BackgroundHotchkiss, R. S., Strasser, A., McDunn, J. E., & Swanson, P. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0901217 · Cited by 1,154
Self-citationThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Self-citationEmerging connectivity of programmed cell death pathways and its physiological implications
Bedoui, S., Herold, M. J., & Strasser, A. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0270-8 · Cited by 979
Self-citationThirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Delbridge, A. R. D., Grabow, S., Strasser, A., & Vaux, D. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.17 · Cited by 752
Self-citationCell Death Pathways in Photodynamic Therapy of Cancer
Mroz, P., Yaroslavsky, A., Kharkwal, G. B., & Hamblin, M. R. (2011) · Cancers · doi:10.3390/cancers3022516 · Cited by 704
“When unleashed by death signals, they switch off survival function by inserting their BH3 domain into a groove on their pro-survival relatives [55].”
BackgroundSCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
Inuzuka, H., Shaik, S., Onoyama, I., Gao, D., Tseng, A., Maser, R. S., Zhai, B., Wan, L., Gutierrez, A., Lau, A. W., et al. (2011) · Nature · doi:10.1038/nature09732 · Cited by 632
Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557
The BCL-2 protein family, BH3-mimetics and cancer therapy
Delbridge, A. R. D., & Strasser, A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.50 · Cited by 531
Self-citationDeciphering the rules of programmed cell death to improve therapy of cancer and other diseases
Strasser, A., Cory, S., & Adams, J. M. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.307 · Cited by 532
Self-citationBCL-2 protein family: attractive targets for cancer therapy
Kaloni, D., Diepstraten, S. T., Strasser, A., & Kelly, G. L. (2023) · Apoptosis · doi:10.1007/s10495-022-01780-7 · Cited by 500
Self-citationSchoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347849 · Cited by 351
The independence of and associations among apoptosis, autophagy, and necrosis
Chen, Q., Kang, J., & Fu, C. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0018-5 · Cited by 346
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
Self-citationCell death pathways: intricate connections and disease implications
Kist, M., & Vucic, D. (2021) · The EMBO Journal · doi:10.15252/embj.2020106700 · Cited by 321
“In addition to its single-agent activity, navitoclax had a great potential for combination therapies, especially those that downregulated Mcl-1, Bcl-2 protein not affected by ABT-263 (Cragg et al , 2009).”
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
Labi, V, & Erlacher, M. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.20 · Cited by 295
“Among all pro-survival BCL-2 proteins, only BCL-2, BCL-xL and BCL-W are bound with relevant affinities by ABT-737 and ABT-263.”
BackgroundBH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Merino, D., Kelly, G. L., Lessene, G., Wei, A. H., Roberts, A. W., & Strasser, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.004 · Cited by 287
Self-citationA Time to Kill: Targeting Apoptosis in Cancer
Koff, J., Ramachandiran, S., & Bernal-Mizrachi, L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16022942 · Cited by 279
“Initial clinical trials of single-agent navitoclax have demonstrated significant activity in B-cell malignancies, especially CLL [53], and several preclinical studies evaluating the addition of navitoclax to conventional cytotoxic agents or targeted therapy show promising results in both solid tumor and hematologic ma…”
BackgroundMalamut, G., El Machhour, R., Montcuquet, N., Martin-Lannerée, S., Dusanter-Fourt, I., Verkarre, V., Mention, J.-J., Rahmi, G., Kiyono, H., Butz, E. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41344 · Cited by 256
Targeting Cdc20 as a novel cancer therapeutic strategy
Wang, L., Zhang, J., Wan, L., Zhou, X., Wang, Z., & Wei, W. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.04.002 · Cited by 251
Anti-CD20 monoclonal antibodies: historical and future perspectives
Lim, S. H., Beers, S. A., French, R. R., Johnson, P. W. M., Glennie, M. J., & Cragg, M. S. (2010) · Haematologica · doi:10.3324/haematol.2008.001628 · Cited by 244
Self-citationNew frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy
Long, J. S., & Ryan, K. M. (2012) · Oncogene · doi:10.1038/onc.2012.7 · Cited by 214
BH3-only proteins in apoptosis at a glance
Happo, L., Strasser, A., & Cory, S. (2012) · Journal of Cell Science · doi:10.1242/jcs.090514 · Cited by 193
“ABT-737 can synergise with conventional anti-cancer agents, as well as with targeted inhibitors of oncogenic kinases (reviewed by Cragg et al., 2009).”
BackgroundSelf-citationAitken, R. J., Findlay, J. K., Hutt, K. J., & Kerr, J. B. (2011) · Reproduction · doi:10.1530/rep-10-0232 · Cited by 182
“Finally, the pro-apoptotic BH3-only proteins, including BCL2L11 (BIM), BBC3 (PUMA), BID, BAD, BMF, BIK, HRK, and PMAIP1 (NOXA), initiate apoptosis signaling by activating BAX and BAK1, either through direct binding or, indirectly, through binding to pro-survival BCL2 family members, thereby unleashing BAX and BAK1 (Cr…”
BackgroundInfluentialTherapeutic targets in triple negative breast cancer
O'Toole, S. A., Beith, J. M., Millar, E. K. A., West, R. H., McLean, A. E. B., Cazet, A., Swarbrick, A., & Oakes, S. R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201361 · Cited by 154
Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes
Al‐Ejeh, F., Kumar, R., Wiegmans, A. P., Lakhani, S. R., Brown, M. P., & Khanna, K. K. (2010) · Oncogene · doi:10.1038/onc.2010.407 · Cited by 158
Waibel, M., Solomon, V. S., Knight, D. A., Ralli, R., Kim, S., Banks, K.-M., Vidacs, E., Virely, C., Sia, K. C. S., Bracken, L. S., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.038 · Cited by 144
“A promising concept to reduce the evolution of tumors with acquired resistance to monotherapies and to improve therapeutic efficacy is by combining targeted therapies to concurrently inhibit two (or more) critical molecules within a single oncogenic network (Cragg et al., 2009; Knight et al., 2010; Maude et al., 2012).”
BackgroundTopp, M. D., Hartley, L., Cook, M., Heong, V., Boehm, E., McShane, L., Pyman, J., McNally, O., Ananda, S., Harrell, M., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.01.008 · Cited by 138
“Two HG-SOCwere found to contain mutations in BRCA1, three HG-SOC had mutations in BRCA2 and a sixth had a mutation in PMS2, a Lynch syndrome family gene associated with OC (de la Chapelle, 2004) (Tables 1 and 2, Supplementary Tables S1, S4).”
BackgroundSelf-citationAPCCdc20 Suppresses Apoptosis through Targeting Bim for Ubiquitination and Destruction
Wan, L., Tan, M., Yang, J., Inuzuka, H., Dai, X., Wu, T., Liu, J., Shaik, S., Chen, G., Deng, J., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.04.022 · Cited by 142
“…T cells acquired resistance to multiple chemotherapeutic drugs, compared to Tax-negative T cells, they are much more sensitive to the BH3-mimetic, ABT-737 (Cragg et al., 2009) that can induce apoptosis through inactivating the anti-apoptotic Bcl-2 family proteins, but not Mcl-1 (Figure S6S).”
InfluentialInhibiting cancer cell hallmark features through nuclear export inhibition
Sun, Q., Chen, X., Zhou, Q., Burstein, E., Yang, S., & Jia, D. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.10 · Cited by 140
Bcl-xL promotes metastasis independent of its anti-apoptotic activity
Choi, S., Chen, Z., Tang, L. H., Fang, Y., Shin, S. J., Panarelli, N. C., Chen, Y., Li, Y., Jiang, X., & Du, Y. N. (2016) · Nature Communications · doi:10.1038/ncomms10384 · Cited by 116
Happo, L., Cragg, M. S., Phipson, B., Haga, J. M., Jansen, E. S., Herold, M. J., Dewson, G., Michalak, E. M., Vandenberg, C. J., Smyth, G. K., et al. (2010) · Blood · doi:10.1182/blood-2010-04-280818 · Cited by 107
Self-citationJilg, S., Reidel, V., Müller‐Thomas, C., König, J., Schauwecker, J., Höckendorf, U., Huberle, C., Gorka, O., Schmidt, B., Burgkart, R., et al. (2015) · Leukemia · doi:10.1038/leu.2015.179 · Cited by 107
Larráyoz, M., Blakemore, S. J., Dobson, R. C., Blunt, M. D., Rose-Zerilli, M. J. J., Walewska, R. J., Duncombe, A. S., Oscier, D. G., Koide, K., Forconi, F., et al. (2015) · Leukemia · doi:10.1038/leu.2015.286 · Cited by 114
Self-citationKoehler, B. C., Scherr, A., Lorenz, S., Urbanik, T., Kautz, N., Elßner, C., Welte, S. E., Bermejo, J. L., Jäger, D., & Schulze‐Bergkamen, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076446 · Cited by 107
“Importantly, deeper mechanistic and structural insights led to the development of small molecule inhibitors targeting antiapoptotic Bcl-2 proteins, so called BH-3 mimetics [27,28].”
Gillings, A. S., Balmanno, K., Wiggins, C. M., Johnson, M. A., & Cook, S. J. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07329.x · Cited by 108
Patterson, C. M., Balachander, S. B., Grant, I., Pop-Damkov, P., Kelly, B., McCoull, W., Parker, J., Giannis, M., Hill, K. J., Gibbons, F. D., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01631-8 · Cited by 95
Pandya Martin, A., Mitchell, C., Rahmani, M., Nephew, K. P., Grant, S., & Dent, P. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.21.9895 · Cited by 98
“promote the toxicity of other therapeutic agents.(23,24) The present studies determined: whether inhibition of BCL-2 family function could restore Lapatinib toxicity in Lapatinib adapted tumor cells and enhance Lapatinib toxicity in naive cells.”
BackgroundThe Essential Role of Evasion from Cell Death in Cancer
Kelly, G. L., & Strasser, A. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-385524-4.00002-7 · Cited by 112
“We predict that combination therapies including BH3-mimetics plus drugs that target onco-proteins that function solely in cancer cells (but not healthy tissues), such as inhibitors of oncogenic kinases, may turn out to have the best efficacy/safety profiles (reviewed in (Cragg et al., 2009)).”
BackgroundMethodInfluentialSelf-citationNangia, V., Siddiqui, F. M., Caenepeel, S., Timonina, D., Bilton, S. J., Phan, N., Gomez-Caraballo, M., Archibald, H. L., Li, C., Fraser, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0277 · Cited by 94
“Therapeutic strategies that cotarget kinase signaling pathways and apoptotic regulators may increase apoptosis and convert cytostatic responses into tumor regressions (13).”
BackgroundRooswinkel, R. W., van de Kooij, B., Verheij, M., & Borst, J. G. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.109 · Cited by 104
“BH3-mimetics represent a new class of anticancer drugs that mimic the function of BH3-only proteins.(9) These compounds act in a tumor-selective way, most likely because tumor cells are ‘primed for death’.”
BackgroundSuryani, S., Carol, H., Chonghaile, T. N., Frismantas, V., Sarmah, C. K., High, L. M., Bornhauser, B. C., Cowley, M. J., Szymanska, B., Evans, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0259 · Cited by 95
“Because evasion of apoptosis is recognized as one of the hallmarks of cancer (3), recent drug development has focused on targeting key components of the apoptosis signaling pathway (4).”
BackgroundMcl-1 Ubiquitination and Destruction
Inuzuka, H., Fukushima, H., Shaik, S., Liu, P., Lau, A. W., & Wei, W. (2011) · Oncotarget · doi:10.18632/oncotarget.242 · Cited by 93
“However, leukemia cells with elevated Mcl-1 expression are found to be refractory to ABT-737 treatment [35, 36] primarily because ABT-737 fails to inactivate Mcl-1 due to a low binding affinity [34].”
BackgroundN-terminally cleaved Bcl-xL mediates ischemia-induced neuronal death
Ofengeim, D., Chen, Y., Miyawaki, T., Li, H., Sacchetti, S., Flannery, R. J., Alavian, K. N., Pontarelli, F., Roelofs, B. A., Hickman, J. A., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3054 · Cited by 78
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo
Mitchell, C., Yacoub, A., Hamed, H. A., Martin, A. P., Bareford, M. D., Eulitt, P. J., Chen, Y., Nephew, K. P., & Dent, P. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.9.13273 · Cited by 74
BCL-2: Long and winding path from discovery to therapeutic target
Schenk, R. L., Strasser, A., & Dewson, G. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.100 · Cited by 77
Self-citationYao, J., Tang, S., Shi, C., Lin, Y., Ge, L., Chen, Q., Ou, B., Liu, D., Miao, Y., Xie, Q., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2119353 · Cited by 79
Platelet senescence and phosphatidylserine exposure
Dasgupta, S. K., Argaiz, E. R., Mercado, J. E. C., Maul, H. O. E., Garza, J., Enríquez, A. B., Abdel‐Monem, H., Prakasam, A., Andreeff, M., & Thiagarajan, P. (2010) · Transfusion · doi:10.1111/j.1537-2995.2010.02676.x · Cited by 76
“ABT737 elicits apoptosis by binding to Bcl-2 and Bcl-XL thereby blocking their inhibitory interaction with the proapoptotic Bax and Bak.23 In contrast to collagenand thrombin-induced phosphatidylserine exposure, cyclosporin A had no effect on ABT737-induced phosphatidylserine exposure.”
BackgroundMatsumoto, M., Nakajima, W., Seike, M., Gemma, A., & Tanaka, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.053 · Cited by 75
Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG
Balakrishnan, I., Danis, E., Pierce, A., Madhavan, K., Wang, D., Dahl, N., Sanford, B., Birks, D. K., Davidson, N., Metselaar, D. S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108286 · Cited by 69
“BH3 mimetics are compounds that bind to the anti-apoptotic BCL2 family of proteins and induce apoptosis in cells (Cragg et al., 2009).”
BackgroundIt's time to die: BH3 mimetics in solid tumors
Kehr, S., & Vogler, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.118987 · Cited by 72
Zhang, S., Li, G., Ma, X.-X., Wang, Y., Liu, G., Feng, L., Zhao, Y., Zhang, G., Wu, Y., Ye, X., et al. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.05.009 · Cited by 65
Overcoming multiple drug resistance mechanisms in medulloblastoma
Othman, R. T., Kimishi, I., Bradshaw, T. D., Storer, L. C. D., Korshunov, A., Pfister, S. M., Grundy, R. G., Kerr, I. D., & Coyle, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-57 · Cited by 79
“Overexpression of anti-apoptotic BCL2 family proteins, such as BCL2, BCL-XL, MCL1 and BCL2A1, has been observed in many types of cancer including MB [38-41].”
BackgroundEffect of dual inhibition of apoptosis and autophagy in prostate cancer
Saleem, A., Dvorzhinski, D., Santanam, U., Mathew, R., Bray, K., Stein, M. N., White, E. P., & DiPaola, R. S. (2012) · The Prostate · doi:10.1002/pros.22487 · Cited by 66
BH3‐only proteins: The death‐puppeteer's wires
Ghiotto, F., Fais, F., & Bruno, S. (2009) · Cytometry Part A · doi:10.1002/cyto.a.20819 · Cited by 72
“It exhibits apoptotic efficacy against several cell tumor cell lines and ex vivo tumor cells (77–80), potentiates the activity of therapeutical agents (80,81), and counteracts human tumor growth in mouse xenograft models (78).”
BackgroundLiew, S. H., Vaithiyanathan, K., Cook, M., Bouillet, P., Scott, C. L., KERR, J. B., Strasser, A., Findlay, J. K., & Hutt, K. J. (2014) · Biology of Reproduction · doi:10.1095/biolreprod.113.116947 · Cited by 60
“BH3-only proteins initiate apoptosis by binding and neutralizing the antiapoptotic BCL-2 family members, including BCL2, BCL-XL, BCL-W, MCL-1, and A1 [18, 19].”
BackgroundSelf-citationSelective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1
Senft, D., Berking, C., Graf, S. A., Kammerbauer, C., Ruzicka, T., & Besch, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030821 · Cited by 58
Wiegmans, A. P., Alsop, A. E., Bots, M. L., Cluse, L. A., Williams, S. P., Banks, K.-M., Ralli, R., Scott, C. L., Frenzel, A., Villunger, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3289 · Cited by 55
“Consistent with this model, combining ABT-737 with proapoptotic stimuli such as conventional chemotherapeutic drugs, g-irradiation and novel "targeted" small molecule and biological agents can induce synergistic apoptosis in tumor cells that are relatively resistant to single agent treatment (39).”
BackgroundSelf-citationVogler, M., Furdas, S. D., Jung, M., Kuwana, T., Dyer, M. J. S., & Cohen, G. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0777 · Cited by 56
Zhan, Y., Carrington, E. M., Ko, H., Vikstrom, I. B., Oon, S., Zhang, J., Vremec, D., Brady, J. L., Bouillet, P., Wu, L., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38966 · Cited by 55
“Since BH3-only proteins are critical for killing of malignant tumors by anticancer drugs, small-molecule compounds that mimic their structure and function (so-called BH3 mimetics) have been developed for cancer therapy (28).”
BackgroundSelf-citationGalmiche, A., Ezzoukhry, Z., François, C., Louandre, C., Sabbagh, C., Nguyen-Khac, E., Descamps, V., Trouillet, N., Godin, C., Regimbeau, J.-M., et al. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0029 · Cited by 50
Zerp, S. F., Stoter, T. R., Hoebers, F. J. P., van den Brekel, M. W. M., Dubbelman, R., Kuipers, G. K., Lafleur, M. V. M., Slotman, B. J., & Verheij, M. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0474-9 · Cited by 52
“BH3-mimetics represent a novel class of selective anti-cancer drugs that mimic the function of BH3-only proteins to induce tumor cell kill, and an appealing strategy to overcome resistance to anti-cancer therapies [10].”
Toward Targeting Antiapoptotic MCL-1 for Cancer Therapy
Kelly, G. L., & Strasser, A. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033510 · Cited by 50
“Many cancers overexpress inhibitors of cell death or lack initiators of apoptosis, and these aberrations diminish the sensitivity of malignant cells to commonly used multitargeted anticancer agents, including targeted inhibitors of oncogenic kinases (Cragg et al. 2009, Strasser et al. 1991).”
BackgroundSelf-citationSakuma, Y., Yamazaki, Y., Nakamura, Y., Yoshihara, M., Matsukuma, S., Nakayama, H., Yokose, T., Kameda, Y., Koizume, S., & Miyagi, Y. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.187 · Cited by 49
“adenocarcinoma cells treated with Src tyrosine kinase inhibitors (TKIs),(8) as ABT-737, the predecessor of ABT-263, can increase the levels of epidermal growth factor receptor (EGFR) TKI-induced apoptosis in EGFR-mutant lung adenocarcinomas.(7,9,10) However, the effect of the combination therapy of ABT-263 and a Src T…”
BackgroundShang, G., Ma, X., & Lv, G. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1387700 · Cited by 47
The two faces of FBW7 in cancer drug resistance
Wang, Z. P., Fukushima, H., Gao, D., Inuzuka, H., Wan, L., Lau, A. W., Liu, P., & Wei, W. (2011) · BioEssays · doi:10.1002/bies.201100101 · Cited by 48
“Therefore, ABT-737 causes many cancer cell types to be refractory to treatment with this drug, primarily because ABT-737 fails to target and inactivate Mcl-1 due to its structural differences [77].”
BackgroundChang, K. H., Sánchez‐Aguilera, A., Shen, S., Sengupta, A., Madhu, M., Ficker, A. M., Dunn, S. K., Davis, A. K., Arnett, J. L., Santho, R. A., et al. (2012) · Blood · doi:10.1182/blood-2011-06-361709 · Cited by 50
Swiecicki, P. L., Bellile, E. L., Sacco, A. G., Pearson, A. T., Taylor, J. M. G., Jackson, T. L., Chepeha, D. B., Spector, M. E., Shuman, A. G., Malloy, K. M., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0364-5 · Cited by 44
“Given the frequent dysregulation of BCL-2 and p53 in R/M HNSCC [30], therapy with BH3 mimetics has the potential to inhibit the hedgehog pathway, inhibit angiogenesis, augment chemo the r apy induced apop to s i s , a nd r eve r s e chemoresistance [16, 18, 31, 32].”
Woo, S. M., Min, K.-J., Seo, B. R., Nam, J.-O., Choi, K. S., Yoo, Y. H., & Kwon, T. K. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.472 · Cited by 45
“and Bak, which results in induction of apoptosis in cancer cells.(6,7) However, ABT-737 has very low affinity for Mcl-1, so”
BackgroundThe impact of phosphatases on proliferative and survival signaling in cancer
Narla, G., Sangodkar, J., & Ryder, C. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2826-8 · Cited by 47
“and intrinsic, allow for the activation of this process both by external signaling to death receptors and by altering the rheostat of Bcl-2 family members in response to various cellular stresses (reviewed in [121, 122]).”
Wu, H., Schiff, D. S., Lin, Y., Neboori, H. J., Goyal, S., Feng, Z., & Haffty, B. G. (2014) · Radiation Research · doi:10.1667/rr13856.1 · Cited by 42
“Studies have shown that targeting Bcl-2 may be of therapeutic benefit (11, 22, 23).”
The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer
Alexandrou, S., George, S. M., Ormandy, C. J., Lim, E., Oakes, S. R., & Caldon, C. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030667 · Cited by 44
“As many cancers are also characterized by aberrant activation of intracellular kinase signaling and p53 [186], it is now thought that targeting direct mediators of the cell survival machinery may serve to improve cytostatic effects of oncogenic kinase inhibitors [187].”
BackgroundNeutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Zoeller, J. J., Vagodny, A., Taneja, K. L., Tan, B. Y., O’Brien, N. A., Slamon, D. J., Sampath, D., Leverson, J. D., Bronson, R. T., Dillon, D. A. R., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0743 · Cited by 41
“In preclinical studies, ABT-263 was found to display remarkable enhancement of cell killing by targeted therapies (4–6) and chemotherapies (7–9), and the clinical benefit in solid tumors is currently under investigation in several clinical trials (10).”
BackgroundClybouw, C., Mérino, D., Nebl, T., Masson, F., Robati, M., O’Reilly, L. A., Hübner, A., Davis, R. J., Strasser, A., & Bouillet, P. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2011.198 · Cited by 41
Self-citationFatty acid synthase ( FASN ) signalome: A molecular guide for precision oncology
Menéndez, J. A., Cuyàs, E., Encinar, J. A., Steen, T. V., Verdura, S., Llop‐Hernández, À., López, J., Serrano‐Hervás, E., Osuna, S., Martín-Castillo, B., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13582 · Cited by 45
“In doing so, they increase the apparent stoichiometry of BH3-only proteins and shift the balance toward apoptosis in cells dependent on these pro-survival proteins [178 – 181 , 187 – 189 ].”
BackgroundKundu, M., Greer, Y. E., Dine, J. L., & Lipkowitz, S. (2022) · Cells · doi:10.3390/cells11233717 · Cited by 41
Kamath, P. R., Sunil, D., Ajees, A. A., Pai, K. S. R., & Biswas, S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.010 · Cited by 37
de Jong, Y., van Maldegem, A. M., Mariño‐Enríquez, A., de Jong, D., Suijker, J., Bruijn, I. H. B., Kruisselbrink, A. B., Cleton-Jansen, A., Szuhai, K., Gelderblom, H. A. J., et al. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.91 · Cited by 36
Juan, W. C., Roca, X., & Ong, S. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095210 · Cited by 39
“Therefore, reduced expression of PTBP1 and hnRNP C could contribute to inferior responses to anticancer agents that rely on BIM expression, such as TKIs [57].”
BackgroundInfluentialGlory, A., Bettaieb, A., & Averill‐Bates, D. A. (2014) · International Journal of Hyperthermia · doi:10.3109/02656736.2014.968641 · Cited by 37
“ABT-737 is effective as a single agent against cancer cell lines including leukaemias, lymphomas, neuroblastoma and small cell lung carcinoma, primary tumour cells and animal models, but it is also useful in combination with other anticancer treatments such as radiation and chemotherapy [28,61,62].”
BackgroundNaik, E., O'Reilly, L. A., Asselin-Labat, M.-L., Merino, D., Lin, A., Cook, M., Coultas, L., Bouillet, P., Adams, J. M., & Strasser, A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100951 · Cited by 31
Self-citationTargeting DNA Polymerase ß for Therapeutic Intervention
Goellner, E. M., Svilar, D., Almeida, K. H., & Sobol, R. W. (2011) · Current Molecular Pharmacology · doi:10.2174/1874-470211205010068 · Cited by 35
Daniëls, V. W., Zoeller, J. J., van Gastel, N., McQueeney, K. E., Parvin, S., Potter, D. S., Fell, G. G., Ferreira, V. G., Yilma, B., Gupta, R., et al. (2021) · Science Signaling · doi:10.1126/scisignal.abc7405 · Cited by 35
Tagscherer, K. E., Fassl, A., Sinkovic, T., Combs, S. E., & Roth, W. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0664-3 · Cited by 33
Broecker‐Preuss, M., Becher-Boveleth, N., Müller, S. P., & Mann, K. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0303-8 · Cited by 35
“Furthermore, the effect of ABT-737 is dependent on the expression of the pro-apoptotic proteins BAK and/or BAX which execute apoptosis when liberated from BCL-2 after ABT-737 treatment [39, 44].”
BackgroundThe BH3-Mimetic ABT-737 Induces Mast Cell Apoptosis In Vitro and In Vivo: Potential for Therapeutics
Karlberg, M., Ekoff, M., Huang, D. C. S., Mustonen, P., Harvima, I. T., & Nilsson, G. P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903656 · Cited by 31
“amajor focus of anticancer research (11, 23).”
Gariboldi, M. B., Taìana, E., Bonzi, M. C., Craparotta, I., Giovannardi, S., Mancini, M., & Monti, E. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.008 · Cited by 31
Song, J., Kim, C., Je-Hwan, L., Jang, S. J., Lee, S.-W., Hwang, J. J., Lim, C., Lee, G., Seo, J., Cho, S. Y., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0030-0 · Cited by 31
“BIM is a BH3-only pro-apoptotic protein that is upregulated by gefitinib treatment in NSCLC harboring activating mutations of EGFR [20, 21].”
BackgroundThe combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice
Brinkmann, K., Grabow, S., Hyland, C. D., Teh, C. E., Alexander, W. S., Herold, M. J., & Strasser, A. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.125 · Cited by 29
Self-citationGarimella, S. V., Gehlhaus, K., Dine, J. L., Pitt, J. J., Grandin, M., Chakka, S., Nau, M. M., Caplen, N. J., & Lipkowitz, S. (2014) · Breast Cancer Research · doi:10.1186/bcr3645 · Cited by 30
“ABT-737 is an inhibitor of BCL-XL (BCL2L1), BCL-w (BCL2L2), and BCL-2 that has been shown to enhance cell death, including in MCF7 breast cancer cells and myeloma cells by binding and inhibiting the activity of antiapoptotic BCL2 family members [30,31].”
Srivastava, A. K., Jaganathan, S., Stephen, L. L., Hollingshead, M. G., Layhee, A., Damour, E., Govindharajulu, J. P., Donohue, J., Esposito, D., Mapes, J. P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3156 · Cited by 30
“Tissues were first minced with fine scissors, then immediately homogenized with a PRO200 homogenizer (PRO Scientific) with MultiGen adaptor and 5 mm generator at a medium (3) setting for 5 seconds.”
MethodThiagarajan, P. S., Wu, X., Zhang, W., Shi, I., Bagai, R. K., Leahy, P. S., Feng, Y., Veigl, M. L., Lindner, D. J., Danielpour, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13307 · Cited by 29
“Last, we also provide further evidence to the efficacy of combined EGFR-TKI and BCL-xL-targeting BH3 mimetic [46] co-inhibitory strategy to dampen the emergence of early adaptive drug escape in EGFR-mutant NSCLC precision therapy.”
Potter, D. S., Kelly, P., Denneny, O., Juvin, V., Stephens, L., Dive, C., & Morrow, C. J. (2014) · Neoplasia · doi:10.1593/neo.131376 · Cited by 28
“In a broad range of cancer cell types, ABT-737 acts synergistically with a variety of conventional and novel chemotherapeutic agents [16], including agents that target the PI3K pathway [17,18].”
BackgroundHerold, M. J., Rohrbeck, L., Lang, M. J., Grumont, R. J., Gerondakis, S., Tai, L., Bouillet, P., Kaufmann, T., & Strasser, A. (2013) · EMBO Reports · doi:10.1038/embor.2013.152 · Cited by 28
“No impact of BimDFoxomutation on El-myc lymphomagenesis Both, the pro-apoptotic BH3-only protein Bim and Foxo transcription factors have been shown to act as tumour suppressors [17,21].”
Self-citationLi, G., Zhang, S., Fang, H., Yan, B., Zhao, Y., Feng, L., Ma, X.-X., & Ye, X. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.018 · Cited by 28
Lü, M., Wang, J., Li, Y., Berenzon, D. P., Wang, X., Mascarenhas, J. O., Xu, M., & Hoffman, R. (2010) · Blood · doi:10.1182/blood-2010-04-279125 · Cited by 27
“ABT-737 is a small-molecule inhibitor that binds the antiapoptotic proteins, Bcl-2, and Bcl-xL, and promotes apoptosis (14).”
BackgroundmicroRNA-10b Is Overexpressed and Critical for Cell Survival and Proliferation in Medulloblastoma
Pal, R., & Greene, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137845 · Cited by 25
“ABT-737 is under early-phase clinical evaluation as single agent therapy for CLL at present, but preclinical studies highlight its potential for use in combined modality therapies [43].”
BackgroundJayanthan, A., Incoronato, A., Singh, A., Blackmore, C. C., Bernoux, D., Lewis, V. A., Stam, R. W., Whitlock, J. A., & Narendran, A. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22760 · Cited by 24
“[37] have suggested that, because of the broader specificities and their ability to curtail critical cytokine-dependent pathways, multi tyrosine kinase inhibitors would be efficacious in combination protocols with ABT-”
Background
Metadata
- Authors
- Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L.
- Affiliations
- Walter and Eliza Hall Institute of Medical Research (AU)
- The Royal Melbourne Hospital (AU)
- Corresponding author
- Cragg, Mark S.
- Scott, Clare L.
- Venue
- Nature Reviews Cancer
- Published
- 2009-04-03
- Volume
- 9
- Issue
- 5
- Pages
- 321-326
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2065336454
- Cited by
- 185
- References
- 58
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 12 · 2021: 8 · 2020: 6 · 2019: 4 · 2018: 8 · 2017: 8 · 2016: 16 · 2015: 17 · 2014: 16 · 2013: 16 · 2012: 15
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- BH3 mimetics, ABT-737, apoptosis, targeted cancer therapy, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biphenyl Compounds, Humans, Nitrophenols, Piperazines, Sulfonamides, Fusion Proteins, bcr-abl, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.